CCL8 and COVID-19: We found our set of differentially regulated chemokines (CCL8, CCL19, and CCL25) intriguing because autoantibodies against CCL8 are augmented in long-term convalescent COVID-19 individuals, and elevated antibodies against the COVID-19 signature chemokine CCL1949 are documented with high confidence in both acute and long-term COVID-19 phases compared to uninfected controls52.